Ani Pharmaceuticals (ANIP) Total Non-Current Liabilities (2011 - 2026)

Ani Pharmaceuticals has disclosed Total Non-Current Liabilities across 15 years of filings, most recently posting $881.4 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 2.09% year-over-year to $881.4 million; the TTM figure through Jun 2026 stood at $881.4 million (up 2.09% YoY), while the FY2025 annual figure was $887.5 million, up 6.14% from the prior year.
• Total Non-Current Liabilities came in at $881.4 million for Q2 2026 at Ani Pharmaceuticals, up from $843.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $891.0 million in Q3 2025 to a low of $366.7 million in Q1 2022.
• Average Total Non-Current Liabilities over 5 years is $605.7 million, with a median of $427.2 million recorded in 2024.
• Year-over-year, Total Non-Current Liabilities gained 1.21% in 2022 and surged 101.59% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $386.5 million in 2022, then increased by 9.4% to $422.8 million in 2023, then jumped by 97.75% to $836.1 million in 2024, then grew by 6.14% to $887.5 million in 2025, then decreased by 0.69% to $881.4 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $881.4 million in Q2 2026, $843.2 million in Q1 2026, and $887.5 million in Q4 2025.